Your browser is no longer supported. Please, upgrade your browser.
Settings
IDRA Idera Pharmaceuticals, Inc. daily Stock Chart
IDRA [NASD]
Idera Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.60 Insider Own0.70% Shs Outstand33.58M Perf Week-6.28%
Market Cap70.66M Forward P/E- EPS next Y-0.68 Insider Trans316.89% Shs Float25.51M Perf Month-15.73%
Income-77.80M PEG- EPS next Q-0.22 Inst Own25.40% Short Float2.02% Perf Quarter-9.13%
Sales0.00M P/S- EPS this Y-31.60% Inst Trans0.76% Short Ratio2.43 Perf Half Y2.96%
Book/sh-0.53 P/B- EPS next Y26.10% ROA-189.00% Target Price- Perf Year-21.13%
Cash/sh0.92 P/C2.28 EPS next 5Y- ROE- 52W Range0.81 - 2.95 Perf YTD14.84%
Dividend- P/FCF- EPS past 5Y4.80% ROI411.30% 52W High-29.15% Beta2.30
Dividend %- Quick Ratio4.50 Sales past 5Y81.80% Gross Margin- 52W Low157.07% ATR0.18
Employees36 Current Ratio4.50 Sales Q/Q- Oper. Margin- RSI (14)43.72 Volatility6.74% 7.08%
OptionableYes Debt/Eq- EPS Q/Q-83.70% Profit Margin- Rel Volume0.74 Prev Close2.12
ShortableYes LT Debt/Eq- EarningsAug 04 AMC Payout- Avg Volume212.50K Price2.09
Recom1.70 SMA20-6.46% SMA50-3.33% SMA20011.98% Volume166,014 Change-1.42%
Sep-24-18Initiated Barclays Overweight $14
Aug-15-18Resumed JP Morgan Overweight $15
Nov-09-17Initiated H.C. Wainwright Buy $4
Apr-25-17Initiated Robert W. Baird Outperform $5
Mar-22-17Initiated JMP Securities Mkt Outperform
Feb-01-17Reiterated Wedbush Outperform $6
Jan-06-16Initiated Wedbush Outperform $6
Jun-15-15Initiated JP Morgan Overweight
Mar-03-14Initiated Cowen Outperform
Mar-24-10Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $10
Nov-21-08Initiated Noble Financial Buy
Oct-27-08Upgrade Susquehanna Financial Negative → Neutral
Aug-06-08Downgrade Canaccord Adams Buy → Hold
May-07-08Downgrade Janney Mntgmy Scott Buy → Neutral
May-02-08Downgrade Susquehanna Financial Neutral → Negative $11
Sep-28-20 08:45AM  
Sep-15-20 07:18AM  
Sep-10-20 10:13AM  
Aug-04-20 04:10PM  
Jul-15-20 08:05AM  
Jun-21-20 11:13PM  
Jun-02-20 08:15AM  
May-01-20 08:00AM  
Apr-30-20 04:35PM  
Apr-23-20 07:30AM  
Apr-21-20 07:30AM  
Apr-10-20 01:49PM  
Apr-07-20 04:05PM  
Mar-12-20 07:30AM  
Mar-06-20 11:14AM  
Mar-05-20 07:00AM  
Jan-14-20 07:00AM  
Dec-24-19 12:05PM  
09:24AM  
Dec-23-19 09:15AM  
Dec-16-19 04:39PM  
Nov-19-19 09:40AM  
Nov-06-19 04:01PM  
Nov-01-19 10:03AM  
Oct-25-19 10:46AM  
Oct-21-19 07:00AM  
Sep-30-19 07:30AM  
Sep-10-19 09:33AM  
Sep-04-19 07:00AM  
Aug-30-19 12:00PM  
Aug-17-19 04:20AM  
Aug-08-19 10:15AM  
09:00AM  
Aug-06-19 04:00PM  
Jul-25-19 10:33AM  
Jul-23-19 07:30AM  
Jul-10-19 01:46PM  
Jun-18-19 04:00PM  
May-10-19 09:35AM  
May-02-19 08:55PM  
04:30PM  
May-01-19 10:32AM  
Apr-29-19 08:34AM  
Apr-10-19 07:00AM  
Apr-02-19 07:00AM  
Mar-14-19 11:21AM  
Mar-07-19 01:55PM  
Mar-06-19 04:30PM  
Feb-27-19 07:00AM  
Jan-23-19 12:55PM  
Jan-18-19 01:08PM  
Jan-04-19 07:30AM  
Dec-18-18 04:05PM  
Dec-17-18 07:00AM  
Dec-14-18 07:00AM  
Dec-12-18 04:01PM  
Dec-11-18 07:20AM  
Dec-08-18 10:02AM  
Nov-27-18 01:01PM  
Nov-06-18 06:35PM  
05:32PM  
04:30PM  
Oct-19-18 06:00AM  
Oct-15-18 07:55AM  
Oct-11-18 08:34AM  
Sep-25-18 03:47PM  
Sep-18-18 04:01PM  
Sep-11-18 07:00AM  
Aug-30-18 07:30AM  
Aug-18-18 08:32AM  
Aug-14-18 07:35AM  
Aug-12-18 11:46AM  
Aug-10-18 08:00AM  
Aug-09-18 07:00AM  
Aug-07-18 03:38PM  
Aug-06-18 02:18PM  
Aug-02-18 06:05PM  
04:57PM  
04:30PM  
02:40PM  
Jul-27-18 11:58AM  
Jul-17-18 08:37AM  
Jul-16-18 07:00AM  
Jul-12-18 08:37AM  
Jul-11-18 05:33PM  
02:34PM  
01:26PM  
11:56AM  
09:41AM  
08:15AM  
Jul-10-18 06:00PM  
05:36PM  
04:35PM  
04:01PM  
Jun-27-18 07:20AM  
Jun-23-18 12:01AM  
Jun-20-18 04:20PM  
Jun-14-18 07:09AM  
Jun-13-18 10:28AM  
07:00AM  
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. The company was founded in 1989 and is based in Exton, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pillar Invest Corp10% OwnerJul 13Buy1.72749,9931,289,9885,427,697Jul 15 06:16 PM
Pillar Invest Corp10% OwnerApr 07Buy1.523,039,5144,620,0616,260,832Apr 09 06:44 PM
Pillar Invest Corp10% OwnerJan 29Sale1.7617,25030,4383,254,442Feb 26 05:12 PM
Pillar Invest Corp10% OwnerJan 28Sale1.7612,53222,0813,271,692Feb 26 05:12 PM
Pillar Invest Corp10% OwnerJan 27Sale1.7715,00026,5503,284,224Feb 26 05:12 PM
YINGLING JONATHAN MICHAELChief Scientific OfficerJan 07Sale1.781,7423,10116,358Jan 10 08:16 AM
MILANO VINCENTPresident & CEOJan 07Sale1.783,0065,35286,560Jan 10 08:14 AM
Kirby John J.Chief Financial OfficerJan 07Sale1.789111,62216,437Jan 10 08:11 AM
Fletcher Robert C.Sr. VP, Bus. Dev. & StrategyJan 07Sale1.781,6152,87516,485Jan 10 08:09 AM
Lim Bryant DavidSVP and General CounselJan 07Sale1.781,6032,85421,240Jan 10 08:07 AM
Pillar Invest Corp10% OwnerNov 08Sale2.449,00021,9603,299,224Nov 08 06:56 PM
Pillar Invest Corp10% OwnerNov 07Sale2.4510,00024,5003,308,224Nov 08 06:56 PM
Pillar Invest Corp10% OwnerNov 06Sale2.50100,000249,5603,318,224Nov 08 06:56 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.